Atrion Co. (NASDAQ:ATRI) Chairman Emile A. Battat Purchases 1,000 Shares

Atrion Co. (NASDAQ:ATRI) Chairman Emile A. Battat acquired 1,000 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were purchased at an average price of $686.25 per share, for a total transaction of $686,250.00. Following the purchase, the chairman now directly owns 148,673 shares of the company’s stock, valued at $102,026,846.25. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Shares of ATRI traded up $6.98 during mid-day trading on Friday, reaching $698.00. 213 shares of the stock traded hands, compared to its average volume of 6,422. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of 35.26 and a beta of 0.14. The stock has a fifty day simple moving average of $750.55 and a 200 day simple moving average of $789.38. Atrion Co. has a 12-month low of $671.05 and a 12-month high of $948.03.

Atrion (NASDAQ:ATRI) last posted its quarterly earnings data on Friday, November 1st. The medical instruments supplier reported $5.15 earnings per share (EPS) for the quarter. The company had revenue of $38.88 million for the quarter. Atrion had a net margin of 23.43% and a return on equity of 16.45%.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Monday, December 2nd will be paid a dividend of $1.55 per share. The ex-dividend date of this dividend is Friday, November 29th. This represents a $6.20 dividend on an annualized basis and a dividend yield of 0.89%.

A number of analysts have recently issued reports on the stock. ValuEngine upgraded shares of Atrion from a “sell” rating to a “hold” rating in a research note on Friday, November 8th. BidaskClub lowered shares of Atrion from a “sell” rating to a “strong sell” rating in a research note on Tuesday, November 19th.

Institutional investors and hedge funds have recently bought and sold shares of the company. Squarepoint Ops LLC increased its stake in shares of Atrion by 155.9% in the third quarter. Squarepoint Ops LLC now owns 714 shares of the medical instruments supplier’s stock worth $556,000 after buying an additional 435 shares during the last quarter. Zebra Capital Management LLC increased its stake in shares of Atrion by 28.6% in the third quarter. Zebra Capital Management LLC now owns 521 shares of the medical instruments supplier’s stock worth $406,000 after buying an additional 116 shares during the last quarter. California State Teachers Retirement System increased its stake in shares of Atrion by 1.9% in the third quarter. California State Teachers Retirement System now owns 2,246 shares of the medical instruments supplier’s stock worth $1,750,000 after buying an additional 42 shares during the last quarter. State Street Corp increased its stake in shares of Atrion by 15.7% in the third quarter. State Street Corp now owns 45,494 shares of the medical instruments supplier’s stock worth $35,448,000 after buying an additional 6,182 shares during the last quarter. Finally, Dean Capital Investments Management LLC increased its stake in shares of Atrion by 39.2% in the third quarter. Dean Capital Investments Management LLC now owns 476 shares of the medical instruments supplier’s stock worth $371,000 after buying an additional 134 shares during the last quarter. Institutional investors own 66.05% of the company’s stock.

About Atrion

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

Further Reading: What is Green Investing?

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.